secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-08-26T13:17:16+00:00
Accession:  0001599298-26-000074
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit partner Akeso reports positive Phase III HARMONi-GI1 results for ivonescimab in biliary tract cancer
--------------------------------------------------------------------------------

- Akeso announced ivonescimab plus chemo showed statistically significant overall survival benefit vs durvalumab plus chemo in first-line advanced BTC.
- HARMONi-GI1, a Phase III study in China sponsored by Akeso, also met key secondary endpoints of progression-free survival and objective response rate.
- This is the first known Phase III study in advanced BTC to show OS superiority against an anti-PD-(L)1 plus chemotherapy regimen.
- Detailed safety and efficacy results will be presented at an upcoming medical congress and published in a peer-reviewed journal.
- Ivonescimab remains investigational in Summit's territories including U.S. and Europe; it is approved for NSCLC in China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000074/0001599298-26-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000074/smmt-20260825.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer